Prothena Biosciences
Nov 26, 2015
Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is a multisystemic, multigenotypic disease resulting from deposition of insoluble ATTR amyloid fibrils in various…
May 26, 2015
Background:
A recent 2-year randomized controlled trial indicated that the transthyretin (TTR) tetramer stabilizer, diflunisal, inhibits polyneuropathy progression…
Chapters:0:00 Welcome and Speaker Introductions3:09 ATTR Treatment Chart3:30 Dr. Tony Urey, Current FDA Approved Treatments for ATTR Amyloidosis21:31 Dr. Chafic…
Image
Video file
- Family Health History Road Trip…
Published: Oct 09, 2023
- FDA Cites Insufficient Evidence of Clinical Meaningfulness -
- No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…
Please join us on January 21st, 2023 from 12:00 pm - 3:00 pm ET for our next webinar on ATTRv and ATTRwt Amyloidosis. Our speakers include Cardiologist Mathew…
This seminar will provide information on the treatment and management of ATTR amyloidosis, as well as a discussion of future directions for research and treatment.…
In February last year, Doherty - now about age 65 - began to experience the same early breathing symptoms his father had had. As an avid hiker who has trekked the…
The treatment uses CRISPR/Cas9 editing technology, a technique derived from bacteria that allows researchers to edit the genome of a cell by specifying regions of…
Investigators have found that intravenous infusion of a CRISPR-Cas9 based gene therapy decreases serum transthyretin (TTR) protein in patients with hereditary TTR…